The global hormone sensitive prostate cancer market leads to an estimated CAGR of 7.2% in the global market during the forecast period and registers a revenue valued at USD 12.44 Billion in 2023, and is expected to cross USD 24.94 Billion by 2033.
| Attributes | Details |
|---|---|
| Hormone Sensitive Prostate Cancer Market Size (2023) | USD 12.44 Billion |
| Hormone Sensitive Prostate Cancer Market Size (2033) | USD 24.94 Billion |
| Hormone Sensitive Prostate Cancer Market CAGR | 7.2% |
The primary goal of key providers is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. They commit to potentially bringing new hope to people with cancer as it drives their purpose and supports accessibility to their cancer medicines.
Moreover, the key players are further dedicated to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. This is expected to surge the adoption of hormone-sensitive prostate cancer.
Key providers have also announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, a certain key player’s anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). As a result, these early findings show anti-tumor activity across three cohorts of the study, which investigated KEYTRUDA in combination with LYNPARZA, docetaxel and prednisone, and enzalutamide - with a safety profile consistent with each therapy alone. This is likely to drive the demand for hormone-sensitive prostate cancer.
Another key market player had announced that it had successfully completed the pivotal phase 3 study for “degarelix,” which is their own novel prostate cancer treatment. While the safety profile was in line with previously conducted studies, this study met the primary objective of reducing levels of testosterone. It is known to be one of the first drugs in the emerging GnRH blocker class of treatments for prostate cancer. This is estimated to support the global hormone-sensitive prostate cancer market growth.
Agonist therapies stimulate the natural hormone’s receptor on the pituitary gland, unlike degarelix. These agents further have a desired clinical effect, but they initially stimulate testosterone production before shutting it down.
Additionally, the market player has received approval from the U.S. Food and Drug Administration (FDA) for degarelix. Following the issuance of a potential trade name that is still under review with the FDA, the market player is immediately expected to begin commercialization in the U.S., which is anticipated to propel the adoption of hormone sensitive prostate cancer.
Furthermore, their clinical trials for prostate cancer study investigational medications alone or in combination with other study medications or standard-of-care therapy. They perform these trials to observe if they can help prevent, find, or treat cancer. Key providers claim that there is a lot to consider when one decides to participate in a clinical trial. This is likely to contribute to the global hormone sensitive prostate cancer market growth.
Key providers are creating innovative strategies for prostate cancer therapy. For instance, recently, a certain market player announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for XTANDI. It was approximated that about 40,000 men in the United States are living with mCSPC, a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone. This is estimated to surge the demand for hormone sensitive prostate cancer. XTANDI, with this approval, has become the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer - non-metastatic, metastatic castration-resistant prostate cancer (CRPC), and mCSPC.
Most prostate cancers are diagnosed as a result of a screening blood test for prostate-specific antigen (PSA) or a digital rectal exam. An elevated concentration of PSA can be the first sign of malignant disease in the prostate. Depending on the scoring of the MRI images, possibly a follow-up biopsy, some guidelines recommend first undergoing a prostate MRI. Further tests, including other medical imaging, might be needed to support the exact diagnosis, staging, and monitoring of patients with malignancy. All these factors are collectively anticipated to expand the global hormone sensitive prostate cancer market size.
Prostate cancer is a general term used for diseased condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (i.e. androgens) and ultimately blocks the action of androgen. The androgen is also responsible for the growth of prostate cancer.
Androgen binds with the receptors and stimulates the expression of specific genes that would be responsible for prostate cancer. However, androgen suppression hormonal therapies are commonly used for the treatment of this cancer. These therapies acts by reducing the production of androgen by the testicles or by blocking the action of androgen in the body.
There is an opportunity for the growth of hormone sensitive prostate cancer owing to the rapidly aging population which is the major cause of prostate cancer.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing incidence of hormone sensitive prostate cancers and availability of various treatment modalities like surgery, radiation therapy and cryosurgery are the major factors driving the growth of hormone sensitive prostate cancer treatment market globally.
The driving factor of hormone sensitive prostate cancer market is the. Advancement in technology, personalized medicine, cost effective treatment procedures are few other factors expected provide boost to global hormone sensitive prostate cancer treatment market.
However, limited commercially availability drugs and treatments for this cancer is the challenge restraining the growth of global hormone sensitive prostate cancer treatment market.
Androgen ablation therapy are generally known as the first line of treatment and thus expected to hold maximum revenue share in overall hormone sensitive prostate cancer treatment market. Anti-androgens and GnRH antagonists are usually prescribed for long term which is also expected to surge the market of hormone sensitive prostate cancer.
The increasing incidences of prostate cancer cases increases the demand of hormonal therapies during the forecast period and hence promotes the market growth.
Principal Consultant
Geographically, the global hormone sensitive prostate cancer market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.North America takes the largest share of global hormone sensitive cancer treatment market followed by Europe.
The global hormone sensitive prostate cancer treatment market is expected to grow in future due to increasing investment by multinational companies in cancer research.
Some of the key players in hormone sensitive prostate cancer market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline plc., Ferring International Center S.A., Roche group, Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Bayer AG, and Pfizer Inc.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global hormone sensitive prostate cancer market has been segmented on the basis of treatment, end use and geography.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Treatment 6.2. End User Type 7. Global Market Analysis and Forecast, By Treatment 7.1. Androgen Ablation Therapy 7.2. Anti-androgens 7.3. Chemotherapy 7.4. Targeted Therapy 7.5. Cryotherapy 8. Global Market Analysis and Forecast, By End User Type 8.1. Hospitals 8.2. Clinics 8.3. Cancer Rehabilitation Centers 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. Asia Pacific 9.6. Japan 9.7. Middle East & Africa 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. Japan Sales Analysis and Forecast, by Key Segments and Countries 16. Middle East & Africa Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Treatment and End User Type for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Novartis Pharmaceuticals 19.2. Merc & Co., Inc. 19.3. Bristol-Myers 19.4. Dendreon Corporation 19.5. GlaxoSmithKline plc. 19.6. Ferring International Center S.A. 19.7. Roche group 19.8. Celgen Corporation 19.9. Amgen Inc. 19.10. Teva Pharmaceutical Industries Ltd. 19.11. Bayer AG 19.12. Pfizer Inc.
Explore Healthcare Insights
View Reports
Hormone Sensitive Prostate Cancer Market
